ResearcherSeoul National UniversityActive in the last 2 years
Jinwoo Ahn
Matched on ORCID iD 0000-0001-6425-2723; OpenAlex author ID A5068485081. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 1 paper
Papers 7
- Characteristics of Pancreatic Cancer-associated Ascites and Redefined Criteria for Bacterial Peritonitis. Co-author DOI 10.1097/mpa.0000000000002606↗
- Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. Co-author DOI 10.3389/fmicb.2025.1555479↗
- Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. Co-author DOI 10.4251/wjgo.v17.i2.100167↗
- Prognostic Value of the Metabolic Response on Serial 18F-FDG PET/CT in Pancreatic Cancer. Co-author DOI 10.5009/gnl240458↗
- Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis. Co-author DOI 10.1177/17588359231175441↗
- Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer. Co-author DOI 10.21037/jgo-22-218↗
- Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. Co-author DOI 10.3389/fonc.2022.1050070↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kwangrok Jung · 6 shared papers, 2022–2025 · strength 1.27
- Paper Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. DOI 10.4251/wjgo.v17.i2.100167↗
- Paper Prognostic Value of the Metabolic Response on Serial 18F-FDG PET/CT in Pancreatic Cancer. DOI 10.5009/gnl240458↗
- Paper Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. DOI 10.3389/fmicb.2025.1555479↗
- Jin‐Hyeok Hwang · 6 shared papers, 2022–2025 · strength 1.27
- Paper Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. DOI 10.4251/wjgo.v17.i2.100167↗
- Paper Prognostic Value of the Metabolic Response on Serial 18F-FDG PET/CT in Pancreatic Cancer. DOI 10.5009/gnl240458↗
- Paper Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. DOI 10.3389/fmicb.2025.1555479↗
- Jaihwan Kim · 6 shared papers, 2022–2025 · strength 1.27
- Paper Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. DOI 10.4251/wjgo.v17.i2.100167↗
- Paper Prognostic Value of the Metabolic Response on Serial 18F-FDG PET/CT in Pancreatic Cancer. DOI 10.5009/gnl240458↗
- Paper Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. DOI 10.3389/fmicb.2025.1555479↗
- Jong-Chan Lee · 5 shared papers, 2022–2025 · strength 1.12
- Paper Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. DOI 10.4251/wjgo.v17.i2.100167↗
- Paper Prognostic Value of the Metabolic Response on Serial 18F-FDG PET/CT in Pancreatic Cancer. DOI 10.5009/gnl240458↗
- Paper Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. DOI 10.3389/fmicb.2025.1555479↗
- Bo‐Mi Kim · 3 shared papers, 2023–2025 · strength 0.68
- Paper Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. DOI 10.4251/wjgo.v17.i2.100167↗
- Paper Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. DOI 10.3389/fmicb.2025.1555479↗
- Paper Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evi… DOI 10.1177/17588359231175441↗
- Jae Hyup Jung · 2 shared papers, 2022–2023 · strength 0.33
- Paper Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evi… DOI 10.1177/17588359231175441↗
- Paper Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. DOI 10.3389/fonc.2022.1050070↗
- Woo Hyun Paik · 1 shared paper, 2026 · strength 0.29
- In Rae Cho · 1 shared paper, 2026 · strength 0.29
- Muhan Yeo · 1 shared paper, 2026 · strength 0.29
- Huapyong Kang · 1 shared paper, 2026 · strength 0.29
- Sang Hyub Lee · 1 shared paper, 2026 · strength 0.29
- Jin Ho Choi MD · 1 shared paper, 2026 · strength 0.29
- Ji Kon Ryu · 1 shared paper, 2026 · strength 0.29
- Kyoung Un Park · 1 shared paper, 2025 · strength 0.23
- Dong‐Won Ahn · 1 shared paper, 2022 · strength 0.16
- Jong-chan Lee · 1 shared paper, 2022 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.